Department of Dermatology, Medical University of Graz, AT-8036 Graz, Austria.
Acta Derm Venereol. 2018 Apr 27;98(5):501-505. doi: 10.2340/00015555-2885.
Treatment recommendations for pityriasis rubra pilaris (PRP) are based solely on case reports and small case series, as to-date no randomized controlled trials are available. We present here a case series of 3 patients and a literature review of 28 studies treating a total of 116 patients, with the aim of providing data regarding efficacy and safety of methotrexate in the treatment of PRP. Methotrexate was effective in our patients; the review showed an overall response rate of 65.5% with complete clearing in 23.3% and excellent improvement in 17.2%, respectively. After excluding studies with other concurrent systemic therapies or low reliability, the overall response rate increased to 90.9%, with complete clearing in 40.9% and excellent improvement in 31.8%, respectively. Sixteen adverse reactions, of which 11 were mild, were observed in 15 patients (12.9%). In conclusion, the available literature supports good response rates and safety of methotrexate in PRP.
针对红糠疹(PRP)的治疗建议仅基于病例报告和小病例系列,因为迄今为止尚无随机对照试验。我们在此报告了 3 例患者的病例系列,并对 28 项共治疗 116 例患者的研究进行了文献复习,旨在提供甲氨蝶呤治疗 PRP 的疗效和安全性数据。甲氨蝶呤在我们的患者中有效;综述显示,总体缓解率为 65.5%,完全缓解率为 23.3%,显著改善率为 17.2%。排除其他同时进行的全身治疗或可靠性较低的研究后,总体缓解率提高至 90.9%,完全缓解率为 40.9%,显著改善率为 31.8%。在 15 例患者(12.9%)中观察到 16 种不良反应,其中 11 种为轻度。总之,现有文献支持甲氨蝶呤治疗 PRP 的良好疗效和安全性。